ClinicalTrials.gg
CompletedNCT01489995Updated Dec 18, 2013

Migalastat Food Effect Study

A Phase 1 interventional study of A (migalastat) and B (migalastat) in Fabry Disease, sponsored by Amicus Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-12-18.

Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing migalastat in Fabry Disease — 2 open to participants now, 3 under way, 3 of them phase 3. migalastat · Fabry Disease.

Enrollment
10th of 20
20 · median 20
Started
2011
with 4 others
Phase 1
3 of 20
none open now
Registered
9th of 20
by date
Lead sponsor
17 of 20
Amicus Therapeutics

Among the 20 studies testing migalastat in Fabry Disease, this one is the 10th largest by enrollment, is one of 5 that started in 2011, is one of 3 in phase 1, and was the 9th registered.

Fabry Disease

244 studies on the registry are indexed under Fabry Disease; 54 are open to participants now.

Browse Fabry Disease studies →

Open to participants now

2 of the 20 studies testing migalastat in Fabry Disease are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About migalastat

migalastat: first FDA approval 2018 (GALAFOLD), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 44 Fabry Disease studies recruiting now, 31 (70%) set no upper age limit and 11 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing migalastat in Fabry Disease, or all of them as a file.
02

Study summary

A 5-period crossover study to evaluate the effect of meal type and timing on migalastat HCl pharmacokinetics in healthy male and female subjects. Subjects will be randomly assigned to 1 of 5 treatment sequences and will receive each treatment over the course of 5 weekly periods.

Read the detailed description

This is a Phase 1, randomized, open-label, 5-period crossover study to evaluate the effect of meal type and timing on migalastat HCl pharmacokinetics in healthy male and female subjects between the ages of 18 and 65 years. A total of 20 subjects will be enrolled such that approximately 14 evaluable subjects complete dosing and critical assessments. Subjects will be randomly assigned to 1 of 5 treatment sequences and will receive each treatment over the course of 5 successive weekly periods including a single dose of migalastat HCl 150 mg in the fasting state as the reference treatment. There will be at least a 7-day washout period between each dose of migalastat HCl and a follow-up visit approximately 7 to 10 days after the last dose in Period 5.

All subjects will be screened within 28 days of admission to the clinical unit. In each period, subjects will check in to the clinical unit the day prior to drug administration and have relevant assessments to ensure continued eligibility for dose administration. On Day 1 of each period, subjects will receive a single dose of migalastat HCl within 1 of the following 5 treatment regimens as follows:

  • 150 mg migalastat HCl in the fasting state (reference arm)
  • 150 mg migalastat HCl with simultaneous consumption of a glucose drink
  • 150 mg migalastat HCl 1 hour before consumption of a high fat meal
  • 150 mg migalastat HCl 1 hour before consumption of a light meal
  • 150 mg migalastat HCl 1 hour after consumption of a light meal

Subjects will be confined to the clinical unit for 24 hours after dosing with serial blood samples collected for PK analysis. Safety will be assessed throughout the study by monitoring clinical laboratory tests, ECGs, physical examinations, vital signs, and AEs.

03

Conditions studied

  • Fabry Disease

Keywords

  • Food effect
  • GR181413A
  • AT1001
  • migalastat hydrochloride
  • Lysosomal storage disorders
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female aged 18 to 65 years inclusive
  • Healthy, as determined by study physician
  • Capable of giving

Exclusion criteria

Exclusion Criteria:

  • Positive for or and/or C viruses
  • History of drug or alcohol abuse or addiction within 2 years
  • Smoker or consumes tobacco products
  • Participation in a clinical trial within 30 days of scheduled first dose
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Reference

    Fasted

    Drug: A (migalastat)

  • Experimental
    Glucose Drink

    Fed

    Drug: B (migalastat)

  • Experimental
    Before High Fat Meal

    Fed

    Drug: C (migalastat)

  • Experimental
    Before Light Meal

    Fed

    Drug: D (migalastat)

  • Experimental
    After Light Meal

    Fed

    Drug: E (migalastat)

Interventions

  • 150 mg migalastat HCl in the fasting state (reference arm)

  • 150 mg migalastat HCl with simultaneous consumption of a glucose drink

  • 150 mg migalastat HCl 1 hour before consumption of a high fat meal

  • 150 mg migalastat HCl 1 hour before consumption of a light meal

  • 150 mg migalastat HCl 1 hour after consumption of a light meal

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration of migalastat HCl after a single dose

    Cmax

    Time frame: 5 weeks (60 PK timepoints)

  2. Time of occurence of maximum observed plasma concentration of migalastat HCl after a single dose

    tmax

    Time frame: 5 weeks (60 PK timepoints)

  3. Area under the plasma concentration-time curve of migalastat HCl after a single dose from time 0 (before dosing) to infinity

    AUC (0 to infinity)

    Time frame: 5 weeks (60 PK timepoints)

  4. Terminal phase half life of migalastat HCl after a single dose

    t1/2

    Time frame: 5 weeks (60 PK timepoints)

  5. Apparent clearance following oral dosing of migalastat HCl after a single dose

    CL/F

    Time frame: 5 weeks (60 PK timepoints)

  6. Area under the plasma concentration-time curve of migalastat HCl after a single dose from time 0 (before dosing) to the time of the last quantifiable concentration

    AUC (0 to t)

    Time frame: 5 weeks (60 PK timepoints)

Secondary outcomes

  1. Adverse Events

    Time frame: 5 weeks

  2. Clinical Laboratory Tests

    Time frame: 5 weeks

  3. Vital Signs

    Time frame: 5 weeks

  4. ECGs

    Time frame: 5 weeks

  5. Physical Examination

    Time frame: 5 weeks

07

Study locations

1 site
  • GSK Investigational Site
    Austin, Texas 78744, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2011
First posted
Dec 12, 2011
Start
Oct 2011
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Last update
Dec 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01489995
Responsible party
Sponsor
First posted
Dec 12, 2011
Start date
Oct 2011
Primary completion
Dec 2011
Completion
Dec 2011
Last update
Dec 18, 2013

Study contacts

Medical Monitor, Clinical Research
study director · AmicusTherapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Migalastat

Start the discussion